SLNO possible move up comingGaps consistently close on SLNO. We are due for major gap close soon possible 2x to 3x. Massive buying including insiders.
−2.98USD
−38.99 MUSD
19.73 M
About Soleno Therapeutics, Inc.
Sector
CEO
Anish Bhatnagar
Headquarters
Redwood City
Website
Employees (FY)
42
Founded
1999
ISIN
US8342033094
FIGI
BBG0024L5B86
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
SLNO - Long Setup Lots of insider buying in June/July last year at $1.65-2.14. Big % and $ size. Possible entry above 1.20, Stop signal 1.07, Target 1 1.47, Target 2 Momentum. Small option chain but options available.
BIG RISK/REWARD ON SLNODear Traders,
As you can in the chart, SLNO is in the weekly support level, I expect launching toward the targets on the chart very soon.
*** This is not a financial advice, I'm still a beginner trying to share my Road here.
Than you.
SLNO to the Moon then MarsMarket Cap is so small that any Hedge Fund will pump this until trading bots start auto investing. When that happens we can see this stock close to $4.00 then reaching $8.00 based on momentum and FDA approval news.
Just my opinion, not investing advise, trade at your own risk
SLNO - Extreme Oversold Territory Going Long...SLNO - took a dive when the FDA demanded more testing of their latest drug. They are working on that and I suspect that we will see a retrace to 2.32 and possible sideways consolidation as the bulls sheepishly return to this little gem. I'm gonna run towards this as the bulls are running away. Be g
SLNO - Long Setup Watch for break of 2.78. Stop signal 2.47. LOTS of insider buying in June/July 2020. Big $ and Big % . First target 3.27. Second target momentum.
inverse head and shoulders (complex)reversal pattern at an ice line. confirmed breakout w/ a backtest. if this level of the neckline holds you'll see bullish div. on the 4hr. targeting the gap fill w a stop just below the previous low is 4:1 r/r. i picked a couple other peaks for targets beyond that. lil low on volume so position
Soleno Therapeutics, Inc. (SLNO) __NASDAQPrices of Interest 🧐🤔:
$1.96
$2.37
$2.62
Profit prices to consider 🧐🤔:
$4.58
SLNO: Buying the Dip, BullishFirst off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, SLNO (which I been watching for a while), caught my interest again. I think today given the price decrease and retracement expectancies, it currently looks lik
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SLNO is 37.50 USD — it has increased by 0.94% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Soleno Therapeutics, Inc. stocks are traded under the ticker SLNO.
Soleno Therapeutics, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
SLNO stock is 3.53% volatile and has beta coefficient of −3.24. Check out the list of the most volatile stocks — is Soleno Therapeutics, Inc. there?
One year price forecast for Soleno Therapeutics, Inc. has a max estimate of 93.00 USD and a min estimate of 51.00 USD.
SLNO earnings for the last quarter are −0.95 USD per share, whereas the estimation was −0.58 USD resulting in a −64.74% surprise. The estimated earnings for the next quarter are −0.27 USD per share. See more details about Soleno Therapeutics, Inc. earnings.
Yes, you can track Soleno Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
SLNO stock has fallen by 5.04% compared to the previous week, the month change is a 13.59% fall, over the last year Soleno Therapeutics, Inc. has showed a 916.26% increase.
SLNO net income for the last quarter is −11.30 M USD, while the quarter before that showed −10.86 M USD of net income which accounts for −4.01% change. Track more Soleno Therapeutics, Inc. financial stats to get the full picture.
Today Soleno Therapeutics, Inc. has the market capitalization of 1.21 B, it has decreased by 3.59% over the last week.
No, SLNO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, SLNO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Soleno Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 42.00 employees. See our rating of the largest employees — is Soleno Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Soleno Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Soleno Therapeutics, Inc. stock shows the buy signal. See more of Soleno Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Soleno Therapeutics, Inc. future price: according to them, SLNO price has a max estimate of 93.00 USD and a min estimate of 51.00 USD. Read a more detailed Soleno Therapeutics, Inc. forecast: see what analysts think of Soleno Therapeutics, Inc. and suggest that you do with its stocks.